November 24, 2020

Download Ebook Free Gliomas

Diffuse Low-Grade Gliomas in Adults

Diffuse Low-Grade Gliomas in Adults
Author : Hugues Duffau
Publisher : Springer Science & Business Media
Release Date : 2013-03-19
Category : Medical
Total pages :502
GET BOOK

This book presents the latest research pertaining to the diagnosis, therapy and management of diffuse low-grade gliomas (DLGG) in adults, with a particular focus on the path towards individualised therapy for this kind of tumour. Recent research on the natural history of DLGGs and their interaction with the brain has led to new diagnostic and therapeutic strategies which increase survival and quality of life of the patient, and these methods are described in this book.

New Therapeutic Strategies in Low-grade Gliomas

New Therapeutic Strategies in Low-grade Gliomas
Author : Luc Taillandier,Laurent Capelle,Hugues Duffau
Publisher : Nova Publishers
Release Date : 2007
Category : Medical
Total pages :99
GET BOOK

Low-grade glioma (LGG) (grade 2 or G2G) is a brain infiltrative neoplasia, often invading cortical and subcortical functional structures, while displaying as a rule a somewhat indolent course initially (no patent deficit). It affects essentially young, fully active patients, who usually present with seizures. However, these lesions progress relentlessly, and their final fate is anaplastic transformation, leading to neurological impairment and death, with an overall median survival of around 10 years since the onset of symptoms. Due to their apparent biological variability, commonly admitted spontaneous prognostic factors are of limited use if not questionable; consequently, the management of LGGs remains difficult to define (individually), and subject to controversies in the literature. However, most studies have evaluated the eventual impact of treatment(s) independently of the individual natural history and of the global therapeutic strategy. Thus, the goal of the present review is to give new insights regarding the different therapeutic strategies that need to be considered for each patient, and the parameters that can help the decision making. First, it is now possible to benefit from data allowing a better understanding of the natural history of a given LGG: (1) initial tumoral volume (2) tumoral growth rate evaluated on at least two MRIs (3) tumoral metabolic profile, using new radiological methods such as PET and SRM (4) tumoral molecular biology, completing the information provided by classical histopathology. Second, it is mandatory to perform a complete neurological examination, extensive neuropsychological assessment and evaluation of the quality of life from the time of diagnosis throughout the follow-up. Moreover, the analysis of the brain functional (re)organisation and connectivity is needed via the use of new neurofunctional imaging methods (PET, MEG, fMRI, DTI), in order to understand the individual mechanisms of functional compensation in reaction to the glioma growth -- explaining the frequent lack of deficit despite a classical invasion of so called "eloquent" areas. Third, the advantages and limits of each treatment have to be considered for each patient. In this way, the use of intraoperative electrical functional mapping as well as the integration, up to the operating room, of preoperative anatomo-functional data, has allowed the minimisation of the risk of postoperative sequelae, while improving the quality of tumor removal, even in eloquent regions. However, the actual long-term impact of surgery on survival still remains to ascertain. Concerning radiotherapy, the adaptation of doses, fractionation and volume of irradiation has enabled to decrease its risks, especially regarding cognitive functions. Nevertheless, despite an impact on the progression free survival, the effect on the overall survival is not proven. Finally, the recent use of new chemotherapeutic drugs has allowed a better tolerance and a frequent improvement of the quality of life via an impact on seizures, with a stabilisation or even partial regression of the LGG; however, the follow-up is still too short to conclude. On the basis of these (non exhaustive) parameters, we propose in the last part of this book to consider not "a standard treatment", but rather alternative "multiple dynamic therapeutic strategies" adapted to each patient, to be evaluated according to the clinico-radiological evolution of the LGG.

Gliomas

Gliomas
Author : Andreas Deimling
Publisher : Springer Science & Business Media
Release Date : 2009-03-26
Category : Medical
Total pages :259
GET BOOK

Gliomas, which comprise astrocytic, oligodendroglial, and ependymal lesions, are the most frequent primary intracranial tumors. This volume summarizes the enormous advances in our knowledge of gliomas that have occurred during recent years. The first part of the book focuses on the glial tumor entities, with detailed discussion of diagnosis, molecular genetics, and tumor origin. This section also contains a chapter on hereditary tumor syndromes associated with gliomas and the molecular mechanisms underlying these specific diseases. The second part is devoted to the clinical management of gliomas and provides insights into novel developments regarding neuroimaging, surgical management, radiation therapy, adjuvant therapy, experimental approaches, and the neurotoxicity of treatment. The final part of the book addresses angiogenesis and epigenetic regulation of gene expression in gliomas.

Intracranial Gliomas Part II - Adjuvant Therapy

Intracranial Gliomas Part II - Adjuvant Therapy
Author : M.F. Chernov,Y. Muragaki,S. Kesari,I.E. McCutcheon
Publisher : Karger Medical and Scientific Publishers
Release Date : 2018-01-25
Category : Medical
Total pages :252
GET BOOK

Treatment of patients with intracranial gliomas, especially high-grade neoplasms, usually requires postoperative adjuvant therapy. Significant progress in the understanding of tumor biology, technological advances in irradiation delivery, and development of novel antitumor drugs have led to an expansion of the therapeutic arsenal in neuro-oncology. This publication provides a unique review of the various options for adjuvant therapy. Special emphasis is on current evidence-based treatment standards and guidelines, and on perspectives of further improvement in long-term outcomes. Chapters review the histopathological and molecular features of gliomas and describe basic principles and clinical results of fractionated radiotherapy, stereotactic radiosurgery, brachytherapy, use of radiosensitizers, systemic chemotherapy and antiangiogenic therapy. Particular attention is paid to treatment of pediatric patients and to physical and psychological rehabilitation and supportive care at the end of life. This book and its accompanying volumes are mainly directed at neuro-oncologists, radiation oncologists, and other clinicians treating patients with brain tumors.

Malignant Gliomas: RMR V3 I2

Malignant Gliomas: RMR V3 I2
Author : Anonim
Publisher : Demos Medical Publishing
Release Date : 2012-10-09
Category : Medical
Total pages :252
GET BOOK

Radiation Medicine Rounds is a trinary, hard cover periodical designed to provide an up-to-date review of a dedicated radiation medicine topic of interest to clinicians and scientists who are involved in the care of patients receiving radiotherapy. It is intended to serve as both a reference and instructional tool for students, housestaff, fellows, practicing clinicians, medical physicists, cancer biologists, radiobiologists, and interdisciplinary colleagues throughout the oncology spectrum. This issue of Radiation Medicine Rounds discusses the more salient topics surrounding the role of radiation therapy for malignant gliomas. The specialty of radiation therapy has increased in complexity over the years, yet as technology improves, the goal of improving outcomes while decreasing toxicity remains critical. Malignant gliomas remain among the most devastating of all malignancies, yet as conventional treatments (surgery, radiation, and chemotherapy) have become optimized overall survival has improved. The underlying molecular and genetic mechanisms of these tumors are becoming better understood, with one of the most important realizations being that histopathologically identical malignant gliomas often demonstrate very distinct clinical behaviors. Malignant Gliomas provides the practitioner with a current overview of best practices, recent research, and future directions in the management of this complex and challenging cancer.

Gliomas

Gliomas
Author : J. Hekmatpanah
Publisher : Springer Science & Business Media
Release Date : 2012-12-06
Category : Medical
Total pages :166
GET BOOK

When I was asked by the Cancer Teaching Committee of the University of Chicago to set up a Symposium on Brain Tumors, I welcomed the opportunity to do so. But I felt that "Brain Tumors" was far too broad a subject to cover in a day and a half meeting. Furthermore, during the past decade, there have been a great many papers and symposiums on technical advancements in the treatment of benign brain tumors. On the other hand, while gliomas make up somewhere around 50% of all brain tumors, there have certainly been far fewer communications about them. For this reason I thought that it would be highly valuable to invite some of the leading investigators to share with us their experience with gliomas. The hope was to learn the current concepts about these tumors biologically and therapeutically, specifically to find out what we are doing and where we are going in these respects. Naturally all aspects could not be covered. Nevertheless, it was a widely expressed opinion by the speakers that they too learned while they came to teach. It is therefore hoped that the publication of their works and ideas through this mono graph will also be useful for the reader. Most of the manu scripts were handed in at the time of the Symposium, and a few were sent later. Except for minor editorial changes the words are entirely those of the speakers and authors.

Gliomas: New Insights for the Healthcare Professional: 2011 Edition

Gliomas: New Insights for the Healthcare Professional: 2011 Edition
Author : Anonim
Publisher : ScholarlyEditions
Release Date : 2012-01-09
Category : Medical
Total pages :175
GET BOOK

Gliomas: New Insights for the Healthcare Professional: 2011 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Gliomas. The editors have built Gliomas: New Insights for the Healthcare Professional: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Gliomas in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Gliomas: New Insights for the Healthcare Professional: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Avastin and Malignant Gliomas

Avastin and Malignant Gliomas
Author : Thomas C. Chen,Marc C. Chamberlain
Publisher : Bentham Science Publishers
Release Date : 2010-12-28
Category : Medical
Total pages :195
GET BOOK

"Neuro-oncology is an embryonic field of cancer research with a number of clinical trials in progress. However, the prognosis on neuro-oncologic patients has remained poor. Moreover, several small scale phase I/II trials performed have proved to be inconcl"

High-Grade Gliomas

High-Grade Gliomas
Author : Gene H. Barnett
Publisher : Springer Science & Business Media
Release Date : 2007-11-21
Category : Medical
Total pages :495
GET BOOK

This is truly an exciting time in the field of neuro-oncology, particularly in the area of hi- grade gliomas. The management of patients with high-grade gliomas has historically been one of the most challenging and disheartening fields in medicine, where failure is the rule and longevity is the exception. The jaded often state that despite purported advances in surgical and radiotherapeutic techniques and a myriad of clinical trials of medical therapies, the s- vival statistics for glioblastoma have not changed in the last three decades. The nihilism associated with these tumors is such that some practitioners still advise against treatment or even biopsy, recommending palliative care with the diagnosis based only on history and an MRI scan. If the current state-of-the-art in the diagnosis and management of high-grade gliomas was truly so bleak, there would be no reason to compile and publish a monograph on the subject. The fact is that we have recently entered an era where real progress is being made in our understanding and treatment of high-grade gliomas that is directly benefiting some patients. We are slowly but surely chipping away at this problem. One approach has exploited correlations between particular molecular markers and therapeutic response. The first such “breakthrough” in high-grade glioma was the observation that loss of chromosomes 1p and 19q uniformly predict chemosensitivity in anaplastic oligodendrogliomas (1).

Current Understanding and Treatment of Gliomas

Current Understanding and Treatment of Gliomas
Author : Jeffrey Raizer,Andrew Parsa
Publisher : Springer
Release Date : 2014-12-02
Category : Medical
Total pages :184
GET BOOK

This book reviews the significant advances in our understanding of glioma biology that have been achieved during the past decade and describes in detail the resultant new approaches to treatment. Improvements in surgical techniques, radiation therapy, and chemotherapy are comprehensively covered, with discussion of their impact in decreasing patient morbidity and increasing survival. In addition, individual chapters are devoted specifically to current treatment for low-grade gliomas, anaplastic gliomas, and glioblastoma multiforme. Other topics addressed include treatment of the elderly patient, investigating emerging therapies from small molecules to immunotherapy and palliative care. This timely book will be a valuable source of up-to-date information for practitioners and will also be of interest to researchers.

Gliomas: New Insights for the Healthcare Professional: 2013 Edition

Gliomas: New Insights for the Healthcare Professional: 2013 Edition
Author : Anonim
Publisher : ScholarlyEditions
Release Date : 2013-07-22
Category : Medical
Total pages :404
GET BOOK

Gliomas: New Insights for the Healthcare Professional: 2013 Edition is a ScholarlyEditions™ book that delivers timely, authoritative, and comprehensive information about Diagnosis and Screening. The editors have built Gliomas: New Insights for the Healthcare Professional: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Diagnosis and Screening in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Gliomas: New Insights for the Healthcare Professional: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Imaging Gliomas After Treatment

Imaging Gliomas After Treatment
Author : Tommaso Scarabino
Publisher : Springer Science & Business Media
Release Date : 2012-03-12
Category : Medical
Total pages :201
GET BOOK

This atlas is a detailed guide to the imaging appearances of gliomas following treatment with neurosurgery, radiation therapy, and chemotherapy. Normal and pathological findings are displayed in detailed MR images that illustrate the potential modifications due to treatment. Particular emphasis is placed on characteristic appearances on the newer functional MR imaging techniques, including MR spectroscopy, diffusion-weighted imaging, and perfusion imaging. These techniques are revolutionizing neuroradiology by going beyond the demonstration of macroscopic alterations to the depiction of preceding metabolic changes at the cellular and subcellular level, thereby allowing earlier and more specific diagnosis. A key section comprising some 40 clinical cases and more than 500 illustrations offers an invaluable clinical and research tool not only for neuroradiologists but also for neurosurgeons, radiotherapists, and medical oncologists.

Local Therapies for Glioma

Local Therapies for Glioma
Author : M. Westphal,J.-C. Tonn,Z. Ram
Publisher : Springer Science & Business Media
Release Date : 2012-12-06
Category : Medical
Total pages :186
GET BOOK

In addition to surgery and radiotherapy, local treatment modalities for the management of brain tumours are increasingly being developed and clinically tested. This book describes for the first time basic tumour biology as well as all current procedures in progress at the most recent level of knowledge, presented by leading experts in the respective fields. Image guided resection procedures, fluorescence guided surgery, developments in interstitial radiosurgery are addressed, just as intracavitary chemotherapy and all current concepts and studies of interstitial targeted therapy. Owing to its topicality this book will remain for long the standard for this comprehensively treated subject.

Glioma

Glioma
Author : ryuya yamanaka
Publisher : Springer Science & Business Media
Release Date : 2012-05-27
Category : Medical
Total pages :232
GET BOOK

Treatment of glioma is currently one of the most challenging problems in oncology, as well as in neurosurgery. Despite major advances in our understanding of the pathomechanism, diagnosis by imaging and the availability of powerful therapeutic tools, the life expectancy of patients with glioblastoma has only been slightly prolonged and a cure remains elusive. None of the currently available surgical tools, including operative microscopes, lasers and image-guided surgery, can enable the detection and removal of all of the tumor tissue. In recent years, however, the landscape has been changing immeasurably, and molecular studies over the past two decades have identified a variety of genetic aberrations that are specifically associated with individual types of gliomas. In addition, certain molecular abnormalities have been linked to therapy responses, thereby establishing clinical biomarkers and molecular targets, and the use of novel agents is being investigated. These agents have been specifically engineered to exert specific cytotoxicity against gliomas, either on their own as single agents or in combination with other modalities. Moreover, there has been an enormous surge of interest in the area of immunology and immunotherapy, which has been facilitated by our understanding of the molecular basis of gliomas. Although several kinds of immunotherapeutic trials have been undertaken, we still await a great breakthrough in terms of clinical efficacy to prolong the survival time of glioma patients.

Modern Management of High Grade Glioma, Part I, An Issue of Neurosurgery Clinics - E-Book

Modern Management of High Grade Glioma, Part I, An Issue of Neurosurgery Clinics - E-Book
Author : Isaac Yang,Seunggu J. Han
Publisher : Elsevier Health Sciences
Release Date : 2012-04-28
Category : Medical
Total pages :174
GET BOOK

Standard therapy for high grade glioma is a topic that is evolving, timely, and relevant. Guest Editors Isaac Yang, MD and Seunggu Han, MD have assembled a group of experts to highlight the latest updates on various forms of management of high grade glioma. Some of the articles included in this issue focus on Extent of Resection for Glioblastoma; Role of adjuvant radiation therapy; Survival benefit of the Temozolomide protocol; Alternative chemotherapeutic agents; The role of avastin; Radiology; Pseuodprogression and Treatment effect; Pathology; Medical Management; Management of insular gliomas; Use of motor mapping; GBM treatment with clinical trials for surgical resection; Clinical trials with immunotherapy; Clinical trials for small molecule inhibitors; Future role of CED for GBM treatment; Application of a vault nanoparticle therapy for GBM therapy; Management of high grade gliomas in pediatric populations; Targeting Glioma Stem Like Cells with a focus on CD 133; and Potential Role for STAT3 inhibitors in glioblastoma.